| Market Cap | 102.15M | P/E | - | EPS this Y | 3.40% | Ern Qtrly Grth | - |
| Income | -39.11M | Forward P/E | -2.45 | EPS next Y | 50.00% | 50D Avg Chg | -10.00% |
| Sales | 10k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -13.00% |
| Dividend | N/A | Price/Book | 2.02 | EPS next 5Y | - | 52W High Chg | -62.00% |
| Recommedations | 2.30 | Quick Ratio | 5.16 | Shares Outstanding | 64.48M | 52W Low Chg | 189.00% |
| Insider Own | 8.32% | ROA | -59.25% | Shares Float | 44.27M | Beta | 2.05 |
| Inst Own | 34.81% | ROE | -104.49% | Shares Shorted/Prior | 1.82M/2.31M | Price | 1.59 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 235,490 | Target Price | 0.75 |
| Oper. Margin | -408,770.50% | Earnings Date | Nov 1 | Volume | 196,247 | Change | -3.64% |
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
| TD Cowen | Hold | Jul 26, 24 |
| HC Wainwright & Co. | Neutral | Jun 4, 24 |
| HC Wainwright & Co. | Neutral | May 6, 24 |
| HC Wainwright & Co. | Buy | Mar 27, 24 |
| Capital One | Overweight | Dec 22, 23 |
| HC Wainwright & Co. | Buy | Aug 3, 23 |
| HC Wainwright & Co. | Buy | Jun 15, 23 |
| HC Wainwright & Co. | Buy | May 4, 23 |
| HC Wainwright & Co. | Buy | Mar 30, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| JUNIUS DANIEL M | Director Director | May 10 | Buy | 1.56 | 30,000 | 46,800 | 93,250 | 05/11/23 |
| Invus Public Equities, L.P. | 10% Owner 10% Owner | Feb 21 | Buy | 1.8 | 400,000 | 720,000 | 8,489,064 | 02/23/23 |
| Invus Public Equities, L.P. | 10% Owner 10% Owner | Feb 15 | Buy | 1.85 | 1,515,266 | 2,803,242 | 8,089,064 | 02/17/23 |
| Invus Public Equities, L.P. | 10% Owner 10% Owner | Feb 09 | Buy | 3.2419 | 11,451 | 37,123 | 6,573,798 | 02/13/23 |
| SANDELL SCOTT D | 10% Owner 10% Owner | Jan 25 | Sell | 3.19 | 3,652,016 | 11,649,931 | 2,237,196 | 01/27/23 |
| SANDELL SCOTT D | 10% Owner 10% Owner | Jan 05 | Sell | 2.76 | 71,362 | 196,959 | 3,881,933 | 01/06/23 |
| Rock Edwin | Chief Medical Office.. Chief Medical Officer | Dec 22 | Buy | 2.25 | 110,000 | 247,500 | 310,000 | 12/27/22 |
| Magnani John L. | SVP of Research, CSO SVP of Research, CSO | Mar 09 | Sell | 1.09 | 3,227 | 3,517 | 321,033 | 03/10/22 |
| Girard Armand | SVP, Chief Business.. SVP, Chief Business Officer | Mar 09 | Sell | 1.09 | 2,339 | 2,550 | 22,661 | 03/10/22 |
| Hahn Brian M. | SVP Finance, CFO SVP Finance, CFO | Mar 09 | Sell | 1.09 | 2,917 | 3,180 | 36,843 | 03/10/22 |